From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Advanced Oncotherapy – Flip-flop Delay To Fundraise!

By Nigel Somerville, the Deputy Sheriff of AIM | Friday 22 April 2022


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


On 12th April 2022 AIM-listed Advanced Oncotherapy (AVO) announced an equity fundraise of £1.735 million at 25p a pop – a premium to market, but only at par price. We were told that the fundraise has been conducted through a direct subscription with the Company (the "Subscription") for a total of 6,940,000 new ordinary shares. So the money was in the bank, right? Wrong….

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 11:48:00